drugset / Trial / NCT01220596

Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.

NCT01220596

Phase 3 Unknown 228 enrolled Hanyang University Roche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the safety and efficacy of Peginterferon alfa-2a following Entecavir compared with Peginterferon alfa-2a monotherapy in patient with HBeAg positive chronic hepatitis B. * Increased HBeAg seroconversion rate * Increased HBsAg loss rate * To define the best treatment condition for chronic HBV hepatitis patients

Timeline

Start
2010-06
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 0.5 mg Oral
Comparator pegylated interferon-α2a Unknown 180 ug Subcutaneous